Zografos L, Wolin D, Andrews E, Calingaert B, Balabanova Y, Horvat-Brocker A, Tarenz C, Suzart-Woischnik K. Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries. Expert Opin Drug Saf. 2022 Mar;21(3):435-46. doi: 10.1080/14740338.2022.1998451
Davidson D, Stevenson M, Llonch MV, Hsieh A, Brown TM, Slota C, Fehnel S. Development of a novel patient-reported outcome measure symptoms and impacts of familial chylomicronemia syndrome. J Clin Lipidol. 2020 Jul;14(4):P571.
Lavonas EJ, Fries JF, Furst DE, Rothman KJ, Stergachis A, Vaida AJ, Zelterman D, Reynolds KM, Green JL, Dart RC. Comparative risks of non-prescription analgesics: a structured topic review and research priorities. Expert Opin Drug Saf. 2012 Jan 1;11(1):33-44.
Chirila C, Earnshaw SR, Black L, McDade CL, Roskell NS, Shannon PR, Montorsi F, Andriole GL. Economic analysis: randomized, placebo-controlled clinical trial of dutasteride in men at high risk for prostate cancer. J Cancer Sci Ther. 2011;S3(004). doi: 10.4172/1948-5956.S3-004
Leiss JK, Lyden JT, Mathews R, Sitzman KL, Vanderpuije A, Mav D, Kendra MA, Klein C, Humphrey CJ. Blood exposure incidence rates from the North Carolina study of home care and hospice nurses. Am J Ind Med. 2009 Feb 1;52(2):99-104.
Lanes SF, Rothman KJ, Dreyer NA, Soden K. Mortality among workers exposed to glycerol polyglicidyl ether. Am J Ind Med. 1994 May;25(5):689-96. doi: 10.1002/ajim.4700250508
Lanes SF, Rothman KJ, Soden KJ, Amsel J, Dreyer NA. Mortality among synthetic-fiber workers exposed to glycerol polyglycidyl ether. Am J Ind Med. 1994 Jan 1;25(5):689-96.